We are live on ! Find out more
LJPC

La Jolla Pharmaceutical Company
LJPC

Delisted

LJPC was delisted on the 19th of August, 2022.

Back to rankings

65 hedge funds and large institutions have $78.8M invested in La Jolla Pharmaceutical Company in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 19 increasing their positions, 22 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

104% more call options, than puts

Call options by funds: $251K | Put options by funds: $123K

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

2% more funds holding

Funds holding: 64 → 65 (+1)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less capital invested

Capital invested by funds: $82.1M → $78.8M (-$3.25M)

14% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 22

Holders
65
Holders Change
+1
Holders Change %
+1.56%
% of All Funds
1.15%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
7
Increased
19
Reduced
22
Closed
6
Calls
$251K
Puts
$123K
Net Calls
+$128K
Net Calls Change
+$268K

Top Buyers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$793K
2
FMBTD
First Midwest Bank Trust Division
Illinois
+$541K
3
Renaissance Technologies
Renaissance Technologies
New York
+$508K
4
PAM
Premier Asset Management
Illinois
+$329K
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$195K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$2.09M
2
Principal Financial Group
Principal Financial Group
Iowa
-$340K
3
Ameriprise
Ameriprise
Minnesota
-$164K
4
VOYA Investment Management
VOYA Investment Management
Georgia
-$118K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$113K
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
51
BNP Paribas Financial Markets
France
$15.2K -$2.05K -479 -11%
Citigroup
52
Citigroup
New York
$14K +$11.3K +2,656 +275%
EIP
53
Ellis Investment Partners
Pennsylvania
$12K – – –
SWA
54
SOA Wealth Advisors
New York
$7K +$4.47K +1,045 New
Royal Bank of Canada
55
Royal Bank of Canada
Ontario, Canada
$7K +$6.34K +1,484 +550%
AIP
56
Ameritas Investment Partners
Nebraska
$6K – – –
APA
57
American Portfolios Advisors
New York
$5.82K -$5.98K -1,400 -48%
PAM
58
Panagora Asset Management
Massachusetts
$4K +$4.35K +1,018 New
SIC
59
Salem Investment Counselors
North Carolina
$3K – – –
Nisa Investment Advisors
60
Nisa Investment Advisors
Missouri
$2K – – –
Group One Trading
61
Group One Trading
Illinois
$1K +$1.33K +311 New
Walleye Capital
62
Walleye Capital
New York
$69 +$76.5K +17,901 New
AIG
63
American International Group
New York
$41 -$1.29K -301 -3%
Principal Financial Group
64
Principal Financial Group
Iowa
– -$340K -84,296 Closed
VOYA Investment Management
65
VOYA Investment Management
Georgia
– -$118K -29,310 Closed
Fidelity Investments
66
Fidelity Investments
Massachusetts
– -$113K -26,433 -100%
GC
67
Grimes & Company
Massachusetts
– -$102K -25,270 Closed
Squarepoint
68
Squarepoint
New York
– -$52K -12,998 Closed
PIA
69
Powell Investment Advisors
Florida
– -$48K -12,000 Closed
GF
70
Gabelli Funds
New York
– -$40K -10,000 Closed
EI
71
Ellevest Inc
New York
– +$175 +41 New
1 2
3

LJPC Hedge Fund Activity: Q4 2020 in Review

65 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q4 2020, worth a combined $78.8M — down 4% from $82.1M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new LJPC positions and 6 closed out — a net gain of 1 holder — while 19 added to existing stakes and 22 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $793K. The largest seller was Morgan Stanley, cutting an estimated $2.09M.

  • 65 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q4 2020, up from 64 in Q3 2020.
  • Funds reported $78.8M of La Jolla Pharmaceutical Company stock for Q4 2020, down 4% quarter-over-quarter.
  • 7 funds opened new La Jolla Pharmaceutical Company positions in Q4 2020 and 6 closed out, a net change of +1 holder.
  • The largest La Jolla Pharmaceutical Company buyer in Q4 2020 was D.E. Shaw & Co, an estimated $793K added.
  • The largest La Jolla Pharmaceutical Company seller in Q4 2020 was Morgan Stanley, an estimated $2.09M sold.

Based on aggregated 13F filings for Q4 2020.